CD274 and non-small cell lung carcinoma: Collectively, although KRAS mutations may predict the response or outcomes in NSCLC patients treated with anti-PD-1/PD-L1 blockade, its clinical relevance has not been fully proven due to the retrospective nature and insufficient examination of the genetic status.